National Technical Information Service intends to grant the company exclusive U.S. rights to manufacture, use and sell products resulting from patent on "New Antiretroviral Agents and Delivery System for Same," the government announced in a March 31 Federal Register notice. Comments are being accepted until May 30.
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.